MALI
MALI Platform
AI Stock Research

Avoro Capital Advisors LLC: latest 13F holdings

For the quarter ending 30 September 2026, Avoro Capital Advisors LLC reported 30 positions worth $9.7B in total, filed with the SEC on 16 November 2026. The quarter before, it reported $11.1B.

Read the filing at SEC EDGAR
Checked: the cover page's entry count and total value match the holdings table.

Top 30 positions by value

#IssuerClassValueWeightSharesvs quarter before
1UNITED THERAPEUTICS CORPCOMMON$1.5B15.41%2,755,555New
2ASCENDIS PHARMA A/SORDINARY SHARES$1.2B11.87%5,050,000Cut 1.2%
3KRYSTAL BIOTECH INCCOMMON$960.7M9.91%2,888,888New
4ARGENX SESPONSORED ADR$958.9M9.89%1,000,000New
5MADRIGAL PHARMACEUTICALS INCCOMMON$923.9M9.53%1,833,333New
6KYMERA THERAPEUTICS INCCOMMON$835.6M8.62%7,474,747New
7ARROWHEAD PHARMACEUTICALS INCCOMMON$720.0M7.43%11,000,000New
8REVOLUTION MEDICINES INCCOMMON$440.3M4.54%2,145,000New
9CYTOKINETICS INCCOMMON$323.0M3.33%4,900,000New
10DEFINIUM THERAPEUTICS INCCOMMON$268.3M2.77%7,050,000New
11STRUCTURE THERAPEUTICS INCSPONSORED ADS$205.0M2.12%6,555,555Unchanged
12XENON PHARMACEUTICALS INCCOMMON$204.5M2.11%5,500,000New
13VERA THERAPEUTICS INCCOMMON$182.0M1.88%5,635,000New
14UNIQURE NVCOMMON$162.5M1.68%6,727,777New
15CELCUITY INCCOMMON$119.3M1.23%1,500,000New
16TAYSHA GENE THERAPIES INCCOMMON$116.3M1.20%23,888,888New
17OCULAR THERAPEUTIX INCCOMMON$95.0M0.98%12,380,300New
18DAMORA THERAPEUTICS INCCOMMON$80.5M0.83%3,783,000New
19HEMAB THERAPEUTICS HLDGS INCCOMMON$58.4M0.60%1,892,372New
20VIRIDIAN THERAPEUTICS INCCOMMON$51.5M0.53%2,500,000New
21SEPTERNA INCCOMMON$50.9M0.52%1,300,000New
22ABIVAX SASPONSORED ADS$48.3M0.50%488,000New
23SCRIBE THERAPEUTICS INCCOMMON$47.8M0.49%2,598,973New
24FAETH THERAPEUTICS INCCOMMON$41.9M0.43%1,410,000Cut 2.4%
25GH RESEARCH PLCORDINARY SHARES$41.6M0.43%1,770,000Cut 1.7%
26BIOHAVEN LTDCOMMON$36.7M0.38%2,750,000New
27AVALO THERAPEUTICS INCCOMMON$36.5M0.38%2,377,777New
28BRAVEHEART BIO INCCOMMON$25.4M0.26%1,255,000New
29WHITEHAWK THERAPEUTICS INCCOMMON$10.7M0.11%2,849,402New
30LEXEO THERAPEUTICS INCCOMMON$1.8M0.02%525,000New

New this quarter

  • UNITED THERAPEUTICS CORP · $1.5B
  • KRYSTAL BIOTECH INC · $960.7M
  • ARGENX SE · $958.9M
  • MADRIGAL PHARMACEUTICALS INC · $923.9M
  • KYMERA THERAPEUTICS INC · $835.6M
  • ARROWHEAD PHARMACEUTICALS INC · $720.0M
  • REVOLUTION MEDICINES INC · $440.3M
  • CYTOKINETICS INC · $323.0M
  • DEFINIUM THERAPEUTICS INC · $268.3M
  • XENON PHARMACEUTICALS INC · $204.5M

Sold out

  • UNITED THERAPEUTICS CORP · was $1.5B
  • KRYSTAL BIOTECH INC · was $1.1B
  • MADRIGAL PHARMACEUTICALS INC · was $984.4M
  • ARGENX SE · was $927.8M
  • ARROWHEAD PHARMACEUTICALS INC · was $925.6M
  • KYMERA THERAPEUTICS INC · was $857.1M
  • REVOLUTION MEDICINES INC · was $430.2M
  • CYTOKINETICS INC · was $425.9M
  • CELCUITY INC · was $355.7M
  • XENON PHARMACEUTICALS INC · was $348.7M

Reading a 13F

A 13F lists a manager's long positions in US-listed securities at the end of a quarter, filed up to 45 days later. It leaves out short positions, cash and most non-US holdings, so it is a partial, delayed view of a portfolio. Nothing here is investment advice.

Positions are named as the manager filed them. Values are the filing's own, in US dollars; changes compare share counts with the quarter before.

Other managers